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Musculoskeletal disorders (MSDs) are the most frequent cause of disability in Europe. 
Reduced mobility and quality of life of the patients are often associated with pain due to 
chronic inflammation. The inflammatory process, accompanied by a destruction of the 
cartilage and bone tissue, is discussed as a result of (A) the infiltration of immune cells 
into the joints, (B) an altered homeostasis of the joint cavity (synovium) with a critical role 
of bone remodeling cells, and (C) release of inflammatory factors including adipokines in 
the arthritic joint. In addition to the classical medication, low-dose radiation therapy using 
photons or radon spa treatments has shown to reduce pain and improve the mobility 
of the patients. However, the cellular and molecular mechanisms of anti-inflammatory 
effects of radon are yet poorly understood. We analyzed blood and serum samples from 
32 patients, suffering from MSDs, who had been treated in the radon spa in Bad Steben 
(Germany). Before and after therapy, we measured the levels of markers related to bone 
metabolism (collagen fragments type-1, cartilage oligomeric matrix protein, receptor 
activator of NFκB ligand, and osteoprotegerin) in the serum of patients. In addition, 
adipokines related to inflammation (visfatin, leptin, resistin, and adiponectin) were ana-
lyzed. Some of these factors are known to correlate with disease activity. Since T cells 
play an important role in the progression of the disease, we further analyzed in blood 
samples the frequency of pro- and anti-inflammatory T cell subpopulations (CD4+IL17+ 
T cells and CD4+FoxP3+ regulatory T cells). Overall, we found a decrease of collagen 
fragments (CTX-I), indicating decreased bone resorption, presumably by osteoclasts, in 
the serum of MSD patients. We also observed reduced levels of visfatin and a consistent 
trend toward an increase of regulatory T cells in the peripheral blood, both indicating 
attenuation of inflammation. However, key proteins of bone metabolism were unchanged 
on a systemic level, suggesting that these factors act locally after radon spa therapy of 
patients with MSDs.
Keywords: chronic inflammatory diseases, degenerative musculoskeletal disorders, bone metabolism, 
osteoblasts, osteoclasts, adipokines, Treg/Th17 cells, radon spa treatment
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inTrODUcTiOn
Musculoskeletal disorders (MSDs) affect large part of the popula-
tion and can have multiple origins. Given this, MSDs represent 
the highest cause of physical disability (1). Reduced mobility and 
quality of life of the patients are often associated with pain due to 
destructive and inflammatory processes at the respective sites of 
the body (2, 3). A major fraction of patients with MSDs suffers 
from osteoarthritis (OA). The disease is elicited by an unbalanced 
load of bone and cartilage, which in turn is causing attrition, 
succeeded by a progressive inflammatory process. Inflammation 
may become chronic and is then accompanied by further erosion 
of cartilage and bone, but also with concurrent bone formation 
(osteophytes) (4). Even though bone and cartilage destruction 
occurs in rheumatoid arthritis (RA) too, the pathogenesis of 
this autoimmune disease is different; in the pathogenesis of RA, 
inflammation is the trigger and not the consequence of bone and 
cartilage destruction (5).
For the treatment of MSDs, non-steroidal anti-inflammatory 
drugs (NSAIDs), opioids, and corticosteroid injections are 
most commonly used (6). NSAIDs and opioids legitimate only 
temporary treatments of acute or chronic pain as they can have 
significant associated morbidity and do not lead to functional 
improvement (7–9). In addition to the classical pharmacological 
treatment with NSAIDs and physiotherapeutic exercises, low-
dose radiation therapy (LDRT) or radon spa treatment is alterna-
tive or complementary therapies for MSDs (10–12). LDRT, which 
is applied in several fractions with total doses ranging from 3.0 
to 6.0 Gy X-rays, is clinically employed for the treatment of local 
chronic inflammatory diseases (11). In radon spa treatment, the 
radioactive radon-gas evaporating from rocks is used; the estima-
tions for the total effective doses range from 0.05 to 2 mSv. The 
treatment consists of serial baths or repeated visits in mountain 
galleries. Clinical studies suggest that radon exposure has analge-
sic, anti-inflammatory, and immune-modulating effects (13–19). 
However, the underlying cellular and molecular mechanisms are 
largely unknown.
The present study (RAD-ON01) with patients suffering from 
MSDs was conceived for investigating a putative anti-inflamma-
tory effect of radon exposure on the immune and skeletal system. 
To elucidate cellular changes leading to the observed clinical 
benefits from radon exposure, we investigated the serum con-
centrations of markers related to bone metabolism, prominent 
inflammatory key players such as adipokines as well as changes 
in subpopulations of T cells.
In spite of differences in the pathogenesis of RA and OA, the 
destruction of cartilage and bone tissue is discussed in both cases 
as a result of several interconnected processes in arthritic joints, 
namely (A) an infiltration of immune cells into the joint, (B) an 
altered homeostasis of the joint cavity (synovium), (C) an imbal-
ance of bone and cartilage remodeling cells, and (D) a release 
of inflammatory cytokines including adipokines (20–22). 
A consequence of the imbalance between residing cells with 
either catabolic or anabolic functions is an enhancement of car-
tilage degradation and bone erosion. Bone erosion is caused by 
an elevated resorbing activity of osteoclasts (OCs) (23), which can 
be indirectly detected by increased levels of collagen fragments 
(CTX-I); the latter are considered as a marker of cathepsin 
K-mediated bone collagen degradation (24). In the case of arthritic 
disease, it is reported that the ratios of released receptor activator 
of nuclear factor kappa B ligand (RANKL), the OC differentiation 
factor receptor activator of NFκB ligand, and osteoprotegerin 
(OPG) are altered, compared to healthy individuals (21). OPG is 
known to compete with RANKL for receptor binding and is thus 
counteracting the OC stimulating effect of RANKL.
A high abundance of inflammatory cells (T and B  cells, 
macrophages) in the synovial fluid of arthritic patients has 
been reported (25, 26); the presence of these cells contributes to 
destructive processes in joints via cytokine release (e.g., RANKL, 
IL-6, IL-1β, or TNF-α) (27). These cytokines, also adipokines, have 
been identified as regulators of inflammation-related processes 
which can also affect synovium or bone cells (28, 29). Adipokines 
are typically released by adipocytes. Elevated levels of adipokines 
such as adiponectin, visfatin, resistin, and leptin were detected in 
serum and synovia of RA and OA patients (22, 30, 31). In patients 
with RA, a decrease of serum levels of adipokines has been shown 
after combined therapy with infliximab and corticosteroids (32) 
and after treatment with conventional synthetic disease modify-
ing drugs (csDMARDS), which are also used in OA (33, 34).
The working hypothesis of the present study was that radon 
therapy for MSD patients may lead to (1) an inhibition of bone 
resorption, and/or bone formation, and an inhibition of cartilage 
attrition, depending on the stage of the disease and (2) a decrease 
in the serum levels of adipokines. To explore this, in MSD patients 
we measured serum levels of markers related to bone turnover, 
i.e., CTX-I, cartilage oligomeric matrix protein (COMP), OPG, 
and RANKL, as well as adipokines associated with the pathoge-
nesis of RA and OA, i.e., visfatin, adiponectin, leptin, and resistin. 
As adipokines themselves were shown to stimulate and promote 
the proliferation and activity of T cells (35), and since subsets of 
T cells are playing a central role in severity or resolution of inflam-
mation, we suspected (3) an altered ratio of anti-inflammatory 
Treg and inflammatory Th17 cells in the serum of the patients.
MaTerials anD MeThODs
study Design and Patients
We prospectively studied a subgroup of patients enrolled in 
the RAD-ON01 trial with chronic degenerative MSDs of spine 
and/or joints. In March 2013, 100 patients were treated in the 
certified health resort Staatsbad Bad Steben [Bavaria, Germany; 
details published in Ref. (36)]. The radon treatment consisted of 
a series of nine baths with duration of 20 min each over 3 weeks. 
Temperature (34°C) and humidity have been controlled. The 
activity of the radon containing baths was 600 or 1,200 Bq/L, the 
Abbreviations: AS, ankylosing spondylitis; BAP, bone-specific alkaline phos-
phatase; COMP, cartilage oligomeric matrix protein; csDMARDS, conventional 
synthetic disease modifying drugs; CTX-I, collagen fragments type-I; NSAID, 
non-steroidal anti-inflammatory drugs; LDRT, low-dose radiation therapy; MSDs, 
musculoskeletal disorders; OA, osteoarthritis; OC, osteoclast; OCN, osteocalcin; 
OPG, osteoprotegerin; RA, rheumatoid arthritis; RANKL, receptor activator of 
nuclear factor kappa B (NFκB) ligand.
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respective cumulative dose was estimated to be 0.3 mSv (12). The 
study was carried out in accordance with the recommendations 
of the ethical review committee of the Bavarian State Chamber of 
Physicians (Bayerische Landesärztekammer, Munich, Germany, 
ethical approval BLÄK #12131). All patients have granted 
their written informed consent. Patients were included in the 
RAD-ON01 study if they fulfilled the following criteria:
 1. Age of at least 18 years (up to 75 years)
 2. Chronic degenerative MSDs of spine and/or joints
 3. Pain anamnesis of at least 1 year
 4. Pain intensity [visual analog scale (VAS) >4]
 5. Accessibility of the patients (living in close proximity to Bad 
Steben)
 6. Patient’s willingness to cooperate
 7. Patient clarification and agreement
 8. No participation in other studies (3 months before and during 
RAD-ON01 study)
Pain parameters, i.e., individual pain perception was evaluated 
by questionnaires filled in by every patient during regular medical 
examinations, using VAS, ranging from 0 (no pain) to 10 (worst 
pain imaginable).
In this work, in total 32 patients have been analyzed, most of 
them (n = 29) suffering from chronic pain in spine and/or joints. 
The mean age of the patients was 62 years (range 41–75 years). The 
patients did not receive any treatment with anti-inflammatory 
drugs during or after radon therapy. The patients were followed 
up before and in regular intervals after the start of therapy (6, 12, 
18, and 30 weeks after the first radon bath). Medical examina-
tion was performed to measure pain and vascular parameters. 
Peripheral blood was drawn at indicated time points, transported 
to our laboratory and analyzed within 24 h.
The availability of serum from the individual patients was 
variable. The results of measurements, which we performed in 
more than 32 patients, are shown in the supplement (Figures S2 
and S3 in Supplementary Material). Measurements of additional 
factors of bone metabolism obtained in less than 32 patients 
are presented in Figure S1 in Supplementary Material. For the 
analysis of the number of Treg and Th17 cells (Figure 4), before 
(0 weeks) and after therapy (6 weeks), only three patients could 
be analyzed. Therefore, we additionally measured the number 
of Treg and Th17 cells in 11 healthy individuals who were not 
treated with radon. The data from patients and healthy donors 
are displayed separately as indicated in the legend of Figure 4.
Flow cytometric analysis of Treg/Th17 
cell Populations
From the peripheral blood of the patients, mononuclear cells 
(PBMCs) were isolated with BD Vacutainer CPT  cell prepara-
tion tubes (BD Biosciences, Heidelberg, Germany) according to 
the manufacturer’s instructions. Immediately after isolation of 
PBMCs, staining of Treg and Th17 cells was performed with the 
human Th17/Treg phenotyping Kit (BD Pharmingen, Heidelberg, 
Germany) according to manufacturer’s staining protocol. Briefly, 
cells were washed with PBS and stained with markers against 
CD4, IL-17, and FoxP3 (PerCP-Cy5.5-CD4, PE-IL17 and Alexa 
Fluor® 647-FoxP3). Expression of cell surface or intracellular 
markers was assessed using a flow cytometer (FACS Canto II, 
Becton Dickinson, Heidelberg, Germany). A typical dot plot 
and the gating strategy are shown in Figure 4. The frequency of 
cells related to the total number of CD4+ cells was analyzed with 
FlowJo software: CD4+FoxP3+ cells were classified as Treg cells 
and CD4+IL17+ cells as Th17 cells.
serum levels of Markers related to Bone 
remodeling and adipokines
Peripheral blood was taken into serum tubes (SST II Advance, 
BD, #366468) and centrifuged with 1,800 × g for 10 min at room 
temperature. Serum aliquots were stored at −80°C. Markers of 
bone and cartilage metabolism, i.e., serum carboxy-terminal 
collagen crosslinks of type-I collagen (CTX-I), osteoprotegerin 
(OPG), and COMP were determined in aliquots of serum samples, 
using in vitro diagnostic applicable ELISA assays obtained from 
Immunodiagnostic Systems Ltd. (Frankfurt/Main, Germany) 
and Immunodiagnostics AG (Bensheim, Germany). Total soluble 
RANKL (sRANKL) was measured by sRANKL ELISA, purchased 
from BioVendor (Brno, Czech Republic). In addition, levels of 
adipokines were measured in serum samples. ELISA for adi-
ponectin and leptin was purchased from TECOmedical (Basel, 
Switzerland); for visfatin and resistin from AdipoGen (Liestal, 
Switzerland). All measurements were carried out according to the 
manufacturer’s instructions. Duplicate measurements were per-
formed for each patient and each time point investigated. The raw 
data of all measurements are shown in Table S1 in Supplementary 
Material.
statistical analysis
Statistical analysis was performed with two-tailed t-test for 
paired or independent samples after checking for normal dis-
tribution of the data points with D’Agostino and Pearson test. 
For distributions deviating from normal distributions, statistical 
significance was calculated with Wilcoxon matched pairs signed 
rank test (Graph Pad Prism 6, Graph Pad Software, La Jolla, CA, 
USA). Probability values <0.05 were considered significant. 
Spearman’s correlation coefficient (r) was determined to analyze 
the relation between pain perception (VAS) and Visfatin and 
CTX-I, respectively.
resUlTs
serum levels of Markers of Bone 
remodeling
To assess the effects of radon spa treatment on bone remodeling, 
we analyzed the levels of CTX-I, a marker used in clinical dia-
gnostics, in the serum of MSD patients before and at indicated 
time points after radon spa treatment (Figure 1A). The levels of 
CTX-I dropped significantly 12 weeks after radon spa treatment 
and persisted at lower levels up to the end of the observation 
period (week 30). This result indicates decreased bone degrada-
tion as a consequence of radon spa treatment. A more detailed 
analysis of the data showed that the baseline levels were higher for 
FigUre 2 | Effect of radon spa treatment on the levels of (a) total souble, receptor activator of nuclear factor kappa B ligand (sRANKL) and (B) osteoprotegerin 
(OPG) in the serum of patients with musculoskeletal disorders (MSDs), measured at indicated times before (0 weeks) and after the onset of the therapy (6–
30 weeks). Boxplots show the median, Tukey whiskers (median ± 1.5 times interquartile range), mean (+), and outliers (•). N = 32, *P ≤ 0.5, two-tailed t-test.
FigUre 1 | Effect of radon spa treatment on the levels of (a) collagen fragments type-1 (CTX-1) and (B) cartilage oligomeric matrix protein (COMP) in the serum  
of patients with musculoskeletal disorders (MSDs), measured at indicated times before (0 weeks) and after the onset of the therapy (6–30 weeks). Boxplots show 
the median, Tukey whiskers (median ± 1.5 times interquartile range), mean (+), and outliers (•). N = 32, **P ≤ 0.01, ***P ≤ 0.001, Wilcoxon matched-paired  
signed rank test.
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female than male patients (Figure S4 in Supplementary Material). 
This is most likely due to postmenopausal changes related to the 
mean age of the female patients (62 years). The reduced CTX-I 
levels measured after the spa treatment were not accompanied 
by changes in the level of the OC inhibiting calcitonin, measured 
in a lower number of patients and presented in Figure S1D 
in Supplementary Material. To test for cartilage attrition, we 
assessed the serum levels of COMP, a glycoprotein belonging to 
the thrombospondin family (37). We did not find any significant 
changes between serum levels before and after therapy, except a 
slight increase for one time point (18 weeks) (Figure 1B).
Next, we analyzed the serum concentrations of the bone 
remodeling factors sRANKL (Figure 2A) and OPG (Figure 2B). 
The level of total sRANKL, which includes also the fraction of 
RANKL bound to OPG, remained unchanged after radon spa 
treatment. For OPG, a transient and significant decrease was 
detected, which occurred at one time point (18  weeks) after 
treatment.
In addition, we measured an OPG-unbound form of 
sRANKL (38), which we defined as “free” sRANKL (Figure 
S1A in Supplementary Material). No significant changes were 
observed, with only a trend discernible for a decrease at 12 and 
30 weeks posttreatment was observed. Other factors indicating 
changes in the regulation of bone formation, such as BAP and 
osteocalcin (OCN), did not show any significantly modified 
levels after radon spa therapy (Figures S1B,C in Supplementary 
Material).
serum concentration of adipokines
To determine possible changes in the release of adipokines 
elicited by radon spa treatment, levels of selected adipokines 
have been measured in the serum of MSD patients. As shown 
in Figure  3A, the results revealed a significant decrease of 
visfatin levels after onset of the therapy, persisting at 30 weeks 
after start of the treatment. In contrast, the serum levels of 
leptin and resistin were not changed over the follow-up period 
FigUre 3 | Effect of radon spa treatment on the levels of visfatin, leptin, resistin, and adiponectin in serum of patients with musculoskeletal disorders (MSDs). The 
concentration of appropriate adipokines was measured at the indicated weeks before (0 weeks) and after onset of the therapy (6–30 weeks). Boxplots show the 
median, Tukey whiskers (median ± 1.5 times interquartile range), mean (+), and outliers (•). N = 32, *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001, Wilcoxon matched-paired 
signed rank test. (a) Visfatin. (B) Leptin. (c) Resistin. (D) Adiponectin.
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(Figures  3B,C). Analysis of adiponectin levels showed no 
changes over 30 weeks as well (Figure 3D), although adiponec-
tin levels of some patients were decreased after 6 and 12 weeks 
after therapy (not shown).
changed Frequencies of Treg and Th17 
Populations in Peripheral Blood
Using flow cytometry, we evaluated the frequencies of anti-
inflammatory Treg cells and their opponents Th17 cells by intra-
cellular staining of FoxP3 or IL-17, respectively. As shown in 
Figure 4, we observed an increasing fraction of FoxP3-positive 
Treg cells (2.1 to 6.9%, related to the total number of CD4+ 
cells) in patients following therapy (30 weeks) compared to the 
frequencies before treatment and those found in healthy donors 
(P = 0.001). However, the frequencies of IL17+ Th17 cells in the 
peripheral blood of patients were unchanged.
Taken together, the results show that a reduction of bone ero-
sion markers occurs in the serum of MSD patients after radon 
spa therapy, but the systemic changes of factors involved in bone 
metabolism are not pronounced. However, anti-inflammatory 
and immune suppressive effects are suggested by the significantly 
altered systemic levels of the adipokine visfatin and Treg cells.
DiscUssiOn
Our work was embedded in a large study (RAD-ON01 study), 
in which 103 patients suffering from MSDs have been enrolled; 
100 of them were followed up by regular medical examinations 
for 30  weeks after treatment. Long-lasting pain reduction was 
observed for the majority of the patients (36). This is in good 
agreement with results from preceding studies on other patholo-
gies in which analgesic effects and functional improvements after 
radon treatment have been shown [e.g., IMURA (39)].
In the frame of the RAD-ON01 study, further investigations 
performed in parallel with medical examinations were dedicated 
to unravel the cellular and molecular basis of the observed pain 
reduction and functional improvements. So far, detailed immune 
phenotyping on the blood samples from individual patients 
revealed a concomitant modulation of the peripheral immune 
cells (36). In the RAD-ON01 study that we present here, we set 
out to assess in a subset of patients markers of bone metabolism 
and related factors. We detected changes which are potentially 
related to bone metabolism, i.e., a decrease of collagen fragments 
(CTX-I, Figure  1A), a systemic decrease of the inflammatory 
factor visfatin (Figure 3A), and a shift in T cell subpopulations 
(Th17/Treg cells, Figure  4) following radon spa treatment. 
FigUre 4 | Subpopulations of in CD4+Foxp3+ T regulatory cells (Treg) and CD4+IL17+ T cells (Th17), related to the number of CD4+ T cells, isolated from the 
peripheral blood of musculoskeletal disorder (MSD) patients following radon spa treatment. (a) Representative dot plot and gating strategy for analysis of Treg/
Th17 cells. Lymphocyte population was identified in the SSC/FSC dot plot. Only CD4+ cells were analyzed for PE-IL17 and APC-Foxp3 staining. (B) Percentage of 
CD4+Foxp3+ Treg cells in the peripheral blood of 3–20 patients (N = 3 for 0 and 6 weeks, N = 14 for 12 weeks, N = 20 for 18 weeks, and N = 16 for 30 weeks). 
Due to a limited number of samples available before treatment (0 weeks), data were compared with 11 healthy controls. (c) Percentage of CD4+IL17+ T cells in the 
peripheral blood of 3–20 patients (N = 3 for 0 and 6 weeks, N = 14 for 12 weeks, and N = 20 for 18 weeks), compared with 11 healthy controls. The samples at 
30 weeks were lost due to technical problems during measurement. Boxplots show the median, Tukey whiskers (median ± 1.5 times interquartile range), mean (+), 
and outliers (•).*P ≤ 0.5, ***P ≤ 0.001, two-tailed t-test.
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As these results have been obtained in a longitudinal study, we 
can demonstrate for the first time long-lasting pain relief after 
radon intervention in MSD patients occurring concomitantly 
with changes in the immune system and bone erosion.
Comparing our results of MSD patients with data on other 
treatment modalities reveals that CTX-I baseline levels and its 
30% decrease after radon spa therapy (Figure  1A; Table S1 in 
Supplementary Material) matches well with the respective values 
of RA patients after anti-TNF-α therapy (40).
Compiled results from prospective studies in osteoporosis 
patients and different treatment modalities showed a decrease of 
CTX serum levels between 10 and 80% (41). For bisphophonate 
treatment, a decrease of 63% was observed (42). To further 
investigate the relevance of the measured reduction of CTX-I 
levels in MSD patients, we have performed a correlation analysis 
between the CTX-I levels and the individual pain perception of 
the patients. We used data published in Ref. (36), where for the 
same patients pain perception was determined by visual analog 
scales (VAS; 0 = no pain, 10 = worst pain imaginable) as part 
of the regular medical examination (Figure 5A). The Spearman’s 
correlation coefficient was determined (r =  0.2141; P ≤  0.01), 
indicating a positive correlation. This suggests a clear impact 
of radon spa treatment on bone metabolism, in line with the 
observed functional improvements in patients after the same 
type of treatment (36). Here, we also observe a small increase in 
cartilage attrition, a characteristic of early stage OA (Figure 1B). 
This is not consistent with the results obtained for CTX-I levels.
The importance of OPG and RANKL as molecular markers for 
bone formation and resorption, respectively, is well established 
(43, 44). The baseline levels of released protein in MSD patients 
in this study (Figure 2) are comparable to those published for AS 
and RA patients (45–47). However, data on serum levels of OPG 
and RANKL after radon exposure are scarce. Not for patients, but 
for individuals at risk for developing osteoporosis, a persistently 
FigUre 5 | Correlation analysis between VAS pain score (0 = no pain, 10 = worst pain imaginable); data from a RAD-ON01 study published in (36) and CTX-I (a) or 
visfatin (B) in patients with MSD before and after radon treatment. N = 32, Spearman’s rank correlation, *P ≤ 0.5, **P ≤ 0.01.
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increased ratio was reported following subjection to a combina-
tion of radon treatment and physical exercise (48). In other patient 
studies, OPG/RANKL was measured only before and directly 
after therapy. For AS patients, it was reported that the levels of 
both proteins are slightly modified and that this in turn results 
in an increase of the OPG/RANKL ratio (46). Similar changes, 
albeit more pronounced, were observed for RA patients but not 
for OA (49) patients. These results are slightly different from the 
results of the RAD-ON01 study revealing small and transient 
changes of OPG levels in MSD patients, but unchanged levels 
of RANKL (Figure  2; Figure S1A in Supplementary Material). 
No significant changes occurred in other markers indicating a 
calcitonin-mediated regulation of bone resorption (Figure S1D in 
Supplementary Material) or OCN- and BAP-mediated regulation 
of bone formation (Figures S1B,C in Supplementary Material). 
Therefore, we suggest that radon exposure does not lead to per-
sistent systemic changes in the OPG/RANKL pathway in MSD 
patients. This is in good agreement with the unchanged levels of 
TNF-α, an inflammatory cytokine inducing osteoclastogenesis 
(50), which we measured in MSD patients after radon spa treat-
ment (Figure S5 in Supplementary Material). However, an effect 
involving OPG/RANKL may be local and confined to sites of 
bone formation and resorption.
Adipokines are involved in the pathogenesis of RA and other 
autoimmune diseases (28, 51), but the specific influence of adi-
pokines on bone metabolism in different pathologies, including 
OA, is less clear (52). Interestingly, adipokines are produced by 
cells of the adipose tissue, and adipose tissue displays a higher 
solubility for the lipophilic noble gas radon compared to water. 
Thus, we assume an accumulation of radon derived isotopes in 
infrapatellar fat pad of joints, bone marrow and in visceral fat. 
This has already been shown for fatty compounds (53); and our 
own unpublished observations support this view (A. Maier, GSI, 
personal communication). Hence, radon could modulate the 
release of adipokines by fat cells.
To test this hypothesis, we measured the level of adipokines 
in the frame of our study. The results revealed no significant 
changes for adiponectin, resistin, and leptin levels in the 
serum of MSD patients (Figure  3; Table S1 in Supplementary 
Material). In previous studies, pharmacological treatments 
however affected the levels of adiponectin and resistin, although 
the reported effects were not consistent. For example, a reduc-
tion of adiponectin levels has been shown in RA patients after 
a combined corticoid and anti-TNF-α therapy (32), whereas in 
other studies an increase was observed (54). Hence, at present, 
the effects of pharmacological treatments on some adipokines 
remain elusive, possibly related to an impact of the disease stage 
or metabolic alterations. In addition, the relation between high 
levels of the abovementioned adipokines and MSD are contro-
versially discussed (52).
Importantly, for visfatin, high serum levels are reported for 
RA patients and correlate with several disease markers (52, 55). 
In the present study, we revealed that radon therapy causes 
a 50% reduction of the visfatin levels (Figure  3; Table S1 in 
Supplementary Material). This decrease is similar to the baseline 
levels reported for RA patients and the respective reduction 
found in some, albeit not in all studies after anti-TNF-α therapy 
(33, 34). To further assess the relevance of the reduction in visfatin 
levels for pain, we determined the Spearman’s correlation coef-
ficient (r = 0.1798; P ≤ 0.05) using data from Ref. (36), indicating 
a positive correlation with pain perception (Figure 5B). This is in 
line with other studies showing an association of visfatin levels, 
pain, and joint damage (55, 56). We conclude that the decrease 
in visfatin levels and the concomitant lower pain perception in 
the radon-treated MSD patients shown in this study provide 
evidence for the role of visfatin in MSD, which can be targeted 
by a treatment with radiation.
However, in spite of an increased number of studies on 
adipokines (22, 57), it cannot be decided yet, if the decrease in 
visfatin levels elicited by radon or drug treatment is related to 
either bone resorption or to an impact on inflammation. The 
hypothesis of an impact of radon spa treatment on inflamma-
tory processes is endorsed by a trend to an increase in immune 
suppressive and anti-inflammatory Treg cells that we detected by 
the intracellular marker FOXP3 (Figure 4). This is in line with 
the proposed role, which T cells play in the progression of OA 
and RA (29).
cOnclUsiOn
We report here for a subset of MSD patients, enrolled in 
the RAD-ON01 study, a reduction of bone degradation, 
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presumably related to an attenuation of inflammation, medi-
ated by the adipokine visfatin and a changed ratio of the T cell 
subpopulations. The results are in line with pain reduction 
and systemic immune effects, i.e., a shift to anti-inflammatory 
or immune suppressive processes, observed in the frame of 
the RAD-ON01 study (36). However, the reduction of bone 
degradation was not reflected by a modified release of respec-
tive regulatory proteins, i.e., OPG/RANKL, in the serum of 
the patients. Therefore, further investigations on local cellular 
processes in inflamed joints after radon therapy are needed. 
It is noteworthy that with respect to radiotherapy of tumors, 
very low doses, as they might occur in the tumor surround-
ing, normal tissue, can induce an increase of Treg cells. In the 
scenario of a tumor therapy this may contribute to a tumor 
permissive microenvironment, and as such are a possible target 
for immune therapy (58).
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